



FAX

Telecopy/ Facsimile Transmission

Date: 5/17/2004

Pages: 13

of pages including this cover sheet)

(Number

TO: Mr David Hibler

(Attorney, Agent, Firm or Agency)

Serial # 10/010,720 (Docket # 1EX-0382-USA)
(Attorney's Docket Number or Application Number)

281 863 3335
(FAX/Telecopier number)

The following is the text of a forthcoming communication
in the above-captioned application

From: **Maryam Monshipouri Ph.D., Examiner**
Art Unit 1652

Technology Center 1600

Art Unit 1652 FAX Number:

Examiner's Office Number: (571) 272-0932

If you have not received all of the pages of this transmission, please contact the examiner at the office telephone number above.

All FAX machines will be available to receive transmissions 24 hours/day, 7 days/week.

In compliance with 1096 OG 30, the filing date accorded each official FAX transmission will be determined by the FAX machine's stamped date found on the last page of the transmission, unless that date is a Saturday, Sunday or federal holiday within the District of Columbia, in which case the official date of receipt will be the next business day.

Supplementary
Office Action Summary

Application No.

10/010,720

Applicant(s)

WALKE ET AL.

Examiner

Maryam Monshipouri

Art Unit

1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-15 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-15 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date ____. | 6) <input type="checkbox"/> Other: ____. |

Art Unit: 1652

In response to applicant's phone call on 5/14/2004 wherein the applicant indicated that certain claims had been erroneously ignored in the last restriction letter, a substitute restriction letter is hereby prepared as indicated below. The examiner would like to express her apologies due to inadvertent error occurred in the last office action. The last restriction letter is hereby moot.

Supplementary Restriction Letter

Restriction to one of the following inventions is required under 35 U.S.C. 121:

1. Claims 1 and 4, drawn to isolated DNA molecules encoding SEQ ID NO:2, classified in class 536, subclass 23.2.
2. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:4, classified in class 536, subclass 23.2.
3. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:6, classified in class 536, subclass 23.2.
4. Claim 1 and 5, drawn to isolated DNA molecules encoding SEQ ID NO:8, classified in class 536, subclass 23.2.
5. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:10, classified in class 536, subclass 23.2.
- 6.. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:12, classified in class 536, subclass 23.2.
7. Claim 1-3, drawn to isolated DNA molecules encoding SEQ ID NO:14, classified in class 536, subclass 23.2.

Art Unit: 1652

8. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:16, classified in class 536, subclass 23.2.
9. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO: 18, classified in class 536, subclass 23.2.
10. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:20, classified in class 536, subclass 23.2.
11. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:22, classified in class 536, subclass 23.2.
12. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:24, classified in class 536, subclass 23.2.
13. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO: 26, classified in class 536, subclass 23.2.
14. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:28, classified in class 536, subclass 23.2.
15. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO: 30, classified in class 536, subclass 23.2.
16. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:32, classified in class 536, subclass 23.2.
17. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:34, classified in class 536, subclass 23.2.
18. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO: 36, classified in class 536, subclass 23.2.

Art Unit: 1652

19. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO: 38, classified in class 536, subclass 23.2.
20. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:40, classified in class 536, subclass 23.2.
21. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:42, classified in class 536, subclass 23.2.
22. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO: 44, classified in class 536, subclass 23.2.
23. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:46, classified in class 536, subclass 23.2.
24. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO: 48, classified in class 536, subclass 23.2.
25. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:50, classified in class 536, subclass 23.2.
26. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:52, classified in class 536, subclass 23.2.
27. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:54, classified in class 536, subclass 23.2.
28. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:56, classified in class 536, subclass 23.2.
29. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:58, classified in class 536, subclass 23.2.

Art Unit: 1652

30. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:60,
classified in class 536, subclass 23.2.
31. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:6
classified in class 536, subclass 23.
32. Claim 1, drawn to isolated DNA molecules encoding SEQ ID NO:64,
classified in class 536, subclass 23.2.
33. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:2,
classified in class 435, subclass 194..
34. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:4
classified in class 435, subclass 194.
35. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:6
classified in class 435, subclass 194.
36. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:8
classified in class 435, subclass 194.
37. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:10
classified in class 435, subclass 194.
38. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:12
classified in class 435, subclass 194.
39. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:14
classified in class 435, subclass 194.
40. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:16
classified in class 435, subclass 194..

Art Unit: 1652

41. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:18
classified in class 435, subclass 194.
42. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:20
classified in class 435, subclass 194.
43. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:22
classified in class 435, subclass 194.
44. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:24
classified in class 435, subclass 194.
45. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:26
classified in class 435, subclass 194.
46. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:28
classified in class 435, subclass 194..
47. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:30
classified in class 435, subclass 194.
48. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:32
classified in class 435, subclass 194.
50. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:34
classified in class 435, subclass 194.
51. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:36
classified in class 435, subclass 194..
52. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:38
classified in class 435, subclass 194.

Art Unit: 1652

53. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:40 classified in class 435, subclass 194.
54. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:42 classified in class 435, subclass 194.
55. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:44 classified in class 435, subclass 194.
56. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:46 classified in class 435, subclass 194.
57. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:48 classified in class 435, subclass 194.
58. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:50, classified in class 435, subclass 194.
59. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:52 classified in class 435, subclass 194.
60. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:54 classified in class 435, subclass 194.
61. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:56 classified in class 435, subclass 194.
62. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:58 classified in class 435, subclass 194.
63. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:60 classified in class 435, subclass 194.

Art Unit: 1652

64. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:62 classified in class 435, subclass 194.
65. Claim 6, drawn to isolated human ENZ66 protein having SEQ ID NO:64 classified in class 435, subclass 194.
66. Claims 7-11, drawn to methods of identifying compounds useful for treatment of diseases recited in claim 7, using said ENZ66 polypeptides, classified in class 435, subclass 15.
67. Claims 12-13, drawn to methods of treating diseases recited in claim 12, using inhibitors of said ENZ66 polypeptides, classified in class 514, subclass 789.
68. Claims 14-15, drawn to methods of inhibiting said ENZ66 polypeptides, classified in class 435, subclass 15.

The inventions are distinct, each from the other because of the following reasons:

The inventions of Groups 1-65 are patentably distinct each from the other because each invention is directed to a product of unrelated chemical structure and function.

The products of Groups 1-65 are each unrelated to the method of Group 67 because said products are neither made nor used by said method.

ENZ66 polypeptides of (Groups 33-65) and methods of Groups 66 (or 68) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as

Art Unit: 1652

claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case each of the ENZ66 polypeptides of Groups 33-65 may be used in antibody preparation method which is totally different than any of those of Groups 66 an 68.

The methods of Groups 66-68 are patentably distinct each from the other because each method has different steps ad different end-points.

It should be noted that in view of extensive number of inventions present, claims 66-67 , which are each directed to 32 patentably distinct methods of use of ENZ66 polypeptides or inhibitors thereof are Grouped together for simplicity. In case applicant decides to choose an invention from any of the Groups 66-68 inventions he/she is advised to elect both a method and a specific product used.

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or other wise include all the limitations of the allowable product claim will be rejoined in accordance with the provision of MPEP section 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and he rejoined process will be withdrawn, and the rejoined process claims will

Art Unit: 1652

be fully examined for patentability in accordance with 37 CFR 1.104, Thus, to be allowable, the rejoined claims must meet all the criteria for patentability including the requirement of 35 U.S.C. 101, 102, 103 and 112. Until an alerted product claims is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined, See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. section 103(b)," 1184 O.G. 86(March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include limitations of the product claim. **Failure to do so may result in a loss of the right to rejoinder.**

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP section 804.01.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).


Art Unit: 1652

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maryam Monshipouri whose telephone number is (571) 272-0932. The examiner can normally be reached on 7:00 a.m to 4:30 p.m. except for alternate Mondays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnanthapu Achutamurthy can be reached on (571) 272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Maryam Monshipouri Ph.D.